🔎 Trials Near Me

Utama › Kanser Ginjal › Georgia

Kajian klinikal Kanser Ginjal di Georgia

6 kajian untuk Kanser Ginjal sedang mencari peserta di lokasi di Georgia.

Bandar di Georgia

Teks kajian rasmi (Bahasa Inggeris)

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Research Site, Atlanta
  • Research Site, Atlanta
  • Research Site, Newnan
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07011719

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Tennessee Oncology, PLLC- Ringgold, Ringgold
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07227415

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT05536141

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT05433142

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • North Georgia Health System, Gainesville
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Atlanta
  • Massive Bio SYNERGY-AI site, Savannah
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.